GPT and Hypertension: The side effect profile was as expected for the camrelizumab plus rivoceranib group, with the most common grade 3 or 4 adverse effects being hypertension (38%), increase in aspartate aminotransferase (17%), increase in alanine aminotransferase (13%), and hand-foot syndrome (12%).